{"value":{"id":1753370,"askingMemberId":4130,"askingMember":null,"house":"Lords","memberHasInterest":false,"dateTabled":"2025-01-07T00:00:00","dateForAnswer":"2025-01-21T00:00:00","uin":"HL3838","questionText":"To ask His Majesty's Government how many patients self-fund access to ruxolitinib to treat myelofibrosis, which is available privately but not on the NHS.","answeringBodyId":17,"answeringBodyName":"Department of Health and Social Care","isWithdrawn":false,"isNamedDay":false,"groupedQuestions":[],"answerIsHolding":false,"answerIsCorrection":false,"answeringMemberId":347,"answeringMember":null,"correctingMemberId":null,"correctingMember":null,"dateAnswered":"2025-01-13T00:00:00","answerText":"<p>The National Institute for Health and Care Excellence (NICE) recommends ruxolitinib as an option for treating disease-related splenomegaly or symptoms in adults with primary myelofibrosis, also known as chronic idiopathic myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, in people with intermediate-2 or high-risk disease. Ruxolitinib is available to National Health Service patients in line with NICE’s recommendations.</p><p>Information on the number of patients who self-fund ruxolitinib for myelofibrosis is not held centrally.</p>","originalAnswerText":"","comparableAnswerText":"","dateAnswerCorrected":null,"dateHoldingAnswer":null,"attachmentCount":0,"heading":"Ruxolitinib: Finance","attachments":[],"groupedQuestionsDates":[]},"links":[{"rel":"self","href":"/Questions/1753370","method":"GET"}]}